Jardiance contains Empagliflozin, an SGLT2 inhibitor that helps lower blood sugar levels in people with type 2 diabetes. It also reduces the risk of cardiovascular death in patients with diabetes and heart disease.
Indications: Type 2 diabetes mellitus, cardiovascular risk reduction.
Dosage: 25 mg once daily in the morning, with or without food.
Side Effects: Urinary tract infections, increased urination, dehydration, hypoglycemia (when used with insulin or sulfonylureas).
Precautions: Monitor renal function before and during treatment. Not recommended for patients with severe renal impairment.
Storage: Store at room temperature, away from moisture and heat.
| Form | Film Coated Tablets |
| Administration Route | Oral |
| Strength | 25 Mg |
| Salt Composition | Empagliflozin |
| Class | Sodium Glucose Co-Transporter 2 Inhibitor |
| Brand Name | Jardiance |
| Precription Required | As Directed By Doctor |
| Pregnancy Category | Category C |
| Metabolism | Primarily Metabolized In Liver |
| Manufacturer | Boehringer Ingelheim |
| Therapeutic Class | Anti Diabetic |
| Used For | Treatment Of Type 2 Diabetes Mellitus |
| Storage | Store Below 30°C |
| Side Effects | Genital Infections, Urinary Tract Infections, Hypoglycemia |
| Packing Type | Box |
| Packaging Size | 9x10 Tablets |
| Supply By | Medicina Overseas Private Limited |
| Country Of Origin | India |
